Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.61 (
porphobilinogen deaminase
)
637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Successful 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) is dependent on efficient porphyrin synthesis in the inflicted cancer tissue, which is regulated by several enzymes. Irradiation of the tumor excites the light-sensitive porphyrins and results in
ROS
production and cell death. In this study we investigated the effect of the expression levels of two main enzymes in heme biosynthesis, ALA dehydratase (ALAD) and
porphobilinogen deaminase
(
PBGD
), on the capacity of K562 cells to undergo cell death following ALA-PDT. We manipulated
PBGD
and ALAD expression levels by shRNAs and
PBGD
overexpressing plasmid.
PBGD
down-regulation induced an elevation in ALAD activity, while overexpression of
PBGD
reduced ALAD activity, indicating a novel regulation feedback of
PBGD
on ALAD activity. This feedback mechanism enabled partial PpIX synthesis under
PBGD
silencing, whereas ALAD silencing reduced PpIX production to a minimum. ALA-PDT efficacy was directly correlated to PpIX levels. Thus, only ALAD-silenced cells were not affected by ALA+ irradiation, while following
PBGD
silencing, the accumulated PpIX, though decreased, was sufficient for successful ALA-PDT. The alterations in ALAD activity level initiated by changes in
PBGD
expression indicates
PBGD
's central role in heme synthesis. This enables efficient ALA-PDT, even when
PBGD
is not fully active. Conversely, ALAD loss resulted in reduced PpIX synthesis and consequently failure in ALA-PDT, due to the absence of compensation mechanism for ALAD.
...
PMID:The centrality of PBGD expression levels on ALA-PDT efficacy. 2165 22